# NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI

> **NCT05638867** · PHASE4 · RECRUITING · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 3944 (estimated)

## Conditions studied

- Coronary Artery Disease
- Percutaneous Coronary Intervention
- Acute Coronary Syndrome

## Interventions

- **DRUG:** Aspirin + Clopidogrel + Rivaroxaban
- **DRUG:** Aspirin + Clopidogrel

## Key facts

- **NCT ID:** NCT05638867
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-25
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 3944 (ESTIMATED)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05638867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05638867, "NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05638867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*